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Abstract
There is no strong evidence on pharmacogenetics role on the quality of INR control after the initiation phase and on the 
maintenance of stable INR on the long term as measured by the time in therapeutic range (TTR). The benefit of a score such 
as SAMe-TT2R2 is that it can preemptively guide clinicians on whether to start the patient on warfarin or direct oral antico-
agulant. To determine the association between genetic variants in CYP2C9, VKORC1, and CYP4F2 and TTR. To validate 
SAMe-TT2R2 score predictive ability on the quality of anticoagulation in Qatari patients. This is an observational nested 
case–control study that was conducted on a cohort of Qatari patients treated with warfarin with previously identified geno-
type for the CYP2C9, VKORC1, and CYP2F4. The sample size of this cohort was 148 patients. Mean TTR was 62.7 ± 21%. 
TTR was not significantly different among carriers of the CYP2C9*2 &*3, VKORC1(–1639G>A) or CYP4F2*3 compared 
to their non-carriers alleles. None of the factors in the SAMe-TT2R2 score had a significant effect on the TTR except for the 
female gender where TTR was significantly lower in females (n = 89) compared to males (n = 59) (59.6 ± 21% vs. 67.2 ± 20%, 
p = 0.03). Furthermore, patients with SAMe-TT2R2 score of zero had significantly better TTR compared to those with higher 
scores (76.5 ± 17% vs. 61.8 ± 21%, p = 0.04). Logistic regression analysis showed that high SAMe-TT2R2 score was the only 
statistically significant predicting factor of poor INR control (odds ratio (OR) 5.7, 95% confidence interval (CI) 1.1–28.3, 
p = 0.034). Genetic variants have no contribution to the quality of INR control. SAMe-TT2R2 score was predictive for the 
poor quality of anticoagulation in a cohort of Qatari patients.
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Highlights
• SAMe-TT2R2 is a tool that can preemptively guide clini-
cians on whether to start the patient on warfarin or direct 
oral anticoagulant.
• There is no strong evidence on pharmacogenetics role on 
the quality of INR control and TTR after the initiation 
phase.
• This research shows that genetic variants have no contri-
bution to the quality of INR control.
• Our results also indicate that SAMe-TT2R2 score is pre-
dictive for the poor quality of anticoagulation in a cohort 
of Qatari patients.
Introduction
For over 60 years, warfarin has been the mainstay antico-
agulant used in the prevention and treatment of thrombo-
embolic complications in patients with atrial fibrillation, 
venous thromboembolism, prosthetic heart valves, and 
coronary artery disease [1]. Because of the narrow thera-
peutic index of warfarin and the substantial interpatient vari-
ability, careful monitoring of anticoagulation is necessary 
in order to minimize the risks associated with warfarin’s 
inadequate dosing and to ensure optimal outcomes for anti-
coagulated patients [2, 3]. Studies have shown that warfarin 
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dose requirements, time to reach therapeutic level and risk 
of bleeding are influenced by demographic, environmental, 
clinical and genetic factors. In recent years, the substantial 
contribution of genetic variations has been well-defined [4, 
5]. Specifically, several studies showed the considerable con-
tribution of genetic variants in the genes encoding vitamin 
K epoxide reductase complex subunit-1 (VKORC1) and 
cytochrome p450 2C9 (CYP2C9) in warfarin dose variabil-
ity. This contribution differs from one population to another 
depending on the allele frequencies for every population 
[6–9]. In recent work from our group on the effect of genetic 
polymorphisms on warfarin stable dose in Qatari patients, 
we have shown that CYP2C9 and VKORC1 polymorphism 
accounted for 10.4% and 14.8% of warfarin dose variability, 
respectively [10].
There is compelling evidence on the usefulness of phar-
macogenetics at the time of warfarin initiation in order to 
predict warfarin maintenance dose. However, to our knowl-
edge, there is no evidence on the role of pharmacogenetics 
in the quality of INR control after the initiation phase and in 
the maintenance of stable INR on the long term as measured 
by the time in therapeutic range (TTR). TTR is an indica-
tor of the quality of warfarin anticoagulation and is a sur-
rogate marker for thromboembolism and bleeding clinical 
outcomes [11].
Since the approval of direct oral anticoagulants (DOACs) 
in 2010 [12, 13], their use has increased and they are now 
widely adopted by clinicians [13–18]. While DOACs were 
shown to have comparable efficacy and superior safety 
compared to warfarin in phase 3 trials [19–24], factors such 
as adherence and appropriate utilization may affect their 
perceived efficacy and safety. What makes these factors 
even more important in DOACs is the lack of a monitoring 
parameter and/or a surrogate marker to indicate their thera-
peutic level. Compared to warfarin, DOACs have more pre-
dictable therapeutic effect with a fixed-dose regimen, cause 
less intracranial bleeding, do not require routine monitoring, 
and have less drug–drug and drug–food interactions [19, 
25, 26]. These benefits should also be considered in light of 
some potential disadvantages such as the increased risk of 
gastrointestinal side effects (especially for dabigatran and 
rivaroxaban), expense and lack of wide availability of anti-
dote, and contraindication in patients with major renal dys-
function [19, 26–28]. Lastly, the cost of DOACs compared 
to warfarin may be prohibitive for many patients [29].
Among the efforts to aid clinicians in deciding whether to 
start or switch patients on warfarin versus DOACs is the use 
of SAMe-TT2R2 score. This score was derived to discrimi-
nate patients who would be less likely to achieve a good 
TTR with warfarin. In 2013, utilizing data of 2080 patients 
in the Atrial Fibrillation Follow-up Investigation of Rhythm 
Management (AFFIRM) trial, Apostolakis et al. developed 
the new SAMe-TT2R2 score (sex female, age <  60 years, 
medical history [more than two comorbidities], treatment 
[interacting drugs, e.g. amiodarone for rhythm control], 
tobacco use [doubled], race [doubled]) score). The score 
incorporates simple clinical and demographic factors that 
may influence anticoagulation control. It may also predict 
patients who may benefit from warfarin (achieving optimum 
anticoagulation control, as reflected by a good TTR above 
65–70%; SAMe-TT2R2 score = 0–1) from those who may 
not (achieving low TTR and poor anticoagulation control; 
SAMe-TT2R2 score ≥ 2). It was further validated externally 
in a prospective cohort of patients receiving anticoagu-
lant therapy, and it illustrated good discrimination perfor-
mance in both the internal and external validation cohorts 
(c-index, 0.72; 95% CI 0.64–0.795; and c-index, 0.7; 95% 
CI 0.57–0.82, respectively) [30]. Thus, the benefit of a score 
such as SAMe-TT2R2 is that it can preemptively guide clini-
cians on whether to start the patient on warfarin or DOAC. 
In this study, we aim to validate the SAMe-TT2R2 score in 
a cohort of Qatari patients on chronic warfarin treatment 
and to determine the impact of genetic variants in CYP2C9, 
VKORC1, and CYP2F4 on the level of INR control (by 
measuring TTR) at the maintenance phase (post first month 
of treatment). The ultimate objective is to determine if 
SAMe-TT2R2 score has good predictive ability of TTR in 
our cohort and if the incorporation of genetic polymorphism 
data can improve the predictive ability of the score.
Methods
Research design and ethics
This study is an observational nested case–control study that 
was conducted on a cohort of Qatari patients treated with war-
farin at Hamad Medical Corporation (HMC) with previously 
identified genotype for the CYP2C9, VKORC1, and CYP4F2. 
Ethical approvals were obtained from the Institutional Review 
Board (IRB) of HMC, and from Qatar University (QU) IRB.
Study setting and timeline
Patients were recruited from 3 different sites, all of which 
are part of HMC, the biggest medical institution in Qatar. 
These included the anticoagulation clinics at Al-Wakra Hos-
pital, Heart Hospital, and Hamad General Hospital. Patients’ 
INR results were collected from the electronic health record 
(Cerner) for 1 year prior to patient enrollment in the genetic 
study which occurred between September, 2016 and March, 
2017. For patients who were initiated on anticoagulation less 
than 1 year before their enrollment in the genetic study, INR 
results were only collected after the first month of warfarin 
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treatment (to avoid the initiation phase) for 1 year afterwards 
or less depending on the duration of treatment.
Study population and sampling
This study included warfarin-treated patients of Qatari 
nationality (identified as Qataris if they hold Qatari passport). 
Patients were considered eligible if they had been on warfarin 
for at least 6 weeks, had been on a stable warfarin dose for at 
least three consecutive clinic visits with their INR in thera-
peutic range, agreed to participate in the genetic study and 
future-related research and signed a written informed consent 
form. A stable warfarin dose was defined as a dose that did 
not vary by more than 10% between clinic visits [14]. Patients 
were excluded if they had liver cirrhosis, had advanced malig-
nancies, were hospitalized within the previous 4 weeks or had 
a diarrheal or febrile disease within the previous 2 weeks of 
their enrollment in the genetic study. The sample size of this 
cohort was 148 patients.
Data collection and outcome measures
In addition to the collection of INR readings as described 
above, baseline and clinical information including: age, 
gender, weight, smoking status, warfarin indication, con-
comitant medical conditions were collected. The primary 
outcome of our study was TTR which was calculated 
using linear interpolation method of Rosendaal et al. [11]. 
Genotyping data (previously collected) for (CYP2C9 *2 & 
*3) (rs1799853 and rs1057910, respectively), VKORC1-
1639G>A (rs9934438) and for CYP4F2*3 (rs2108622) vari-
ants were presented. SAMe-TT2R2 score was calculated by 
providing one point for the following criteria: sex female, 
age < 60 years, medical history [more than two comor-
bidities], treatment [interacting drugs, e.g. amiodarone for 
rhythm control]. Two points were given to the following 
criteria: tobacco use and race (non-caucasians).
Statistical analysis
Descriptive statistics was used to analyze baseline demo-
graphics. Depending on their normal distribution, numeri-
cal data were presented as mean with standard deviation or 
median and interquartile range. Categorical variables were 
presented as frequencies and percentages. For genetic vari-
ants, Chi-square-Goodness of Fit was used to make sure that 
all allele frequencies fit the Hardy–Weinberg equilibrium. 
Continuous variables were tested for normality tests includ-
ing Kolmogorov–Smirnov and Shapiro–Wilk.
We used independent sample t-test to estimate the differ-
ence in mean TTR between the different genotype groups. 
SAMe-TT2R2 score (median, interquartile range) and TTR 
(mean, standard deviation) were calculated. The effect of 
SAMe-TT2R2 individual factors (example: gender, tobacco 
use etc.) as well as the effect of overall SAMe-TT2R2 (low 
vs. high) on TTR were assessed using independent sample 
t-test. Logistic regression was used to confirm the associ-
ated factors with poor quality of anticoagulation (performed 
twice using < 70% and < 65% as threshold for poor antico-
agulation). Sensitivity, Specificity, positive predictive value 
and negative predictive value and odds ratio of SAMe-TT2R2 
model on poor quality of anticoagulation were explored. A 
P value of less than 0.05 was considered statistically signifi-
cant. All Statistical tests were carried using the IBM Statisti-
cal Package for Social Sciences, SPSS v. 26.0 (IBM Corp., 
Armonk, NY, USA).
Results
Study population characteristics
A total of 148 patients were included in the study. Patients’ 
mean age was 62.6 ± 13 years, 60% of them were female, 
and were mostly obese with an average body mass index 
(BMI) of 32 ± 6.9 kg/m2. Almost two third of the patients 
had atrial fibrillation as the main indication for warfarin, 
while diabetes mellitus and hypertension were the most 
common comorbidities in the cohort. Median (IQR) SAMe-
TT2R2 was 2(1), while mean TTR was 62.7 ± 21%. Details 
of all demographics and baseline characteristics are shown 
in Table 1.
Association of warfarin genetic variants 
with anticoagulation control (TTR)
There was no statistical significant difference in TTR 
between carriers and non-carriers of the minor allele in 
CYP2C9, VKORC1 and CYP4F2 (Table 2).
Association of SAMe‑TT2R2 with anticoagulation 
control (TTR)
None of the factors in the SAMe-TT2R2 score had a signifi-
cant effect on the TTR except for the female gender where 
TTR was significantly lower in females (n = 89) compared to 
males (n = 59) (59.6 ± 21% vs. 67.2 ± 20%, p = 0.03). Addi-
tionally, overall SAMe-TT2R2 score was associated with the 
level of anticoagulation control. However, results were only 
significant when a cut-off of one was used instead of two to 
indicate poor anticoagulation control (TTR was 76.5 ± 17% 
for patients SAMe-TT2R2 score of zero vs. 61.8 ± 21% 
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for patients SAMe-TT2R2 score of one or more, p = 0.04) 
(Fig. 1a, b). Furthermore, a higher proportion of patients 
with TTR ≥ 65% and ≥ 70% were found in the low SAMe-
TT2R2 score group compared to the high SAMe-TT2R2 score 
group (77.8% vs. 43.2%, p = 0.04; and 77.8% vs. 38.1%, 
p = 0.01). And to confirm that the overall SAMe-TT2R2 score 
is the predicting factor for the poor quality of anticoagu-
lation (< 70%) rather than just the female gender, logistic 
regression analysis was performed and high SAMe-TT2R2 
overall score was the only statistically significant predicting 
factor of the model (odds ratio (OR):5.7, 95% confidence 
interval (CI) 1.1–28.3, p = 0.034) (Table 3).
Discussion
An important result from this study is that CYP2C9, 
VKORC1, and CYP2F4 genetic mutations are not associ-
ated with the quality of anticoagulation during maintenance 
phase in a cohort of Qatari warfarin patients. Over the years, 
many have investigated the effect of genetic and non-genetic 
factors on warfarin dosing. Results have shown that the most 
important genes affecting warfarin dose among the different 
populations are the CYP2C9, VKORC1 and CYP4F2 [31]. 
Clinical utility trials were also conducted to investigate the 
ability of genetic-guided dosing to improve clinical out-
comes during warfarin initiation and results were mostly 
positive [4, 5, 32]. On the other hand, there were very few 
studies that investigated the effect of these genetic factors 
on the long-term anticoagulation control with controver-
sial results [33, 34]. In 2015, Park and colleagues collected 
data from 380 Korean patients with atrial fibrillation and 
evaluated genetic (CYP2C9 and VKORC1) and non-genetic 
(SAMe-TT2R2 score) factors associated with TTR [33]. 
VKORC1 1173C>T was the only factor associated with TTR 
while there was no significant effect of SAMe-TT2R2 score 
on the quality of anticoagulation control. In 2018, another 
group from Spain investigated the effect of VKORC1, 
CYP2C9*2, CYP2C9*3, MIR133A2 and SAMe-TT2R2 score 
Table 1  Demographics and baseline characteristics
*Thrombophilia, LV thrombus, or cardiomyopathy
**Amiodarone or digoxin
Variable Total (N = 148)
Age (years) mean ± SD 62.6 ± 13
Gender no. (%)
 Female 89 (60.1)
BMI (kg  m−2) mean ± SD 32 ± 6.9
Smoker no. (%) 11 (7.4)
Weekly warfarin dose (mg/week) median (IQR) 31.5 (21–43.7)
SAMe-TT2R2 score median (IQR) 2 (1)
SAMe-TT2R2 score (%)
 Zero 9 (6)
 1 38 (25.5)
  ≥ 2 101 (68.5)
TTR mean ± SD 62.7 ± 21
TTR < 70% (%) 88 (59.5%)
Indication for warfarin no. (%)
 Atrial fibrillation 97 (65.5)
 Valve replacement 23 (15.5)
 Venous thromboembolism 19 (12.8)
 Other* 9 (6.2)
Concomitant disease no. (%)
 Diabetes 84 (56.8)
 Hypertension 98 (66.2)
 HF 16 (10.8)
 Cancer 3 (2)
 Dyslipidemia 41 (27.5)
Concurrent medications no. (%)
 Statins 102 (68.9)
 Antiplatelets 45 (30.4)
 Antiarrythmics** 28 (18.9)
 Thyroidal hormones 21 (14.2)
Genotype frequencies no. (%)
 VKORC1(-1639G>A)
  GG 39 (26.4)
  AG 78 (52.7)
  AA 31 (20.9)
 CYP2C9*2 & *3
  *1*1 104 (70.3)
  *1*2/*2*2 33 (22.3)
  *1*3/*3*3 11 (7.4)
 CYP4F2*3 (C > T)
  CC 50 (33.8)
  CT 70 (47.3)
  TT 28 (18.9)
Table 2  Effect of pharmacogenetic variants on time in therapeutic 
range
TTR time in therapeutic range
*P value refer to the comparison of TTR between the carriers and the 
non-carriers of the genotype using independent sample T-test
PGX variant TTR P-value*
CYP2C9 *2 & *3
 Carriers (n = 44) 66.9 ± 20.8% 0.108
 Non-carriers (n = 104) 60.9 ± 21%
VKORC1 (-1639 G > A)
 Carriers (n = 107) 63.4 ± 21.2% 0.514
 Non-carriers (n = 41) 60.8 ± 21.1%
CYP4F2*3
 Carriers (n = 98) 64.5 ± 21.1% 0.145
 Non-carriers (n = 50) 59.1 ± 20.9%
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on the level of anticoagulation control [34]. They tested 212 
Spanish patients with nonvalvular atrial fibrillation treated 
with acenocoumarol and found that genetic factors did not 
have any significant effect on the quality of INR control. 
Beside SAMe-TT2R2, body mass index and regular vitamin 
K intake were the only predictors of poor anticoagulation 
control. Racial differences and the interaction effect with 
genetic mutations are among the factors that may have led to 
this contrast in the results between these two studies. Qataris 
and Arabs are considered Caucasians which may explain 
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Fig. 1  a Time in therapeutic range across different SAMe-TT2R2 
scores. Bars represent time in therapeutic range (%TTR) and lines 
represent standard error of the mean across SAMe-TT2R2 scores. b 
Comparison between effect of high versus low SAMe-TT2R2 score 
on time in therapeutic range. Bars represent time in therapeutic range 
(%TTR) and lines represent standard error of the mean in patients 
with SAMe-TT2R2 score of zero versus a score of one or more. P 
value was measured using independent sample T-test
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why results from our study were similar to the Spanish popu-
lation rather than the Korean.
Additionally, results from our study have shown that gen-
der was the only factor among the SAMe-TT2R2 criteria that 
was associated with the quality of anticoagulation in the 
same cohort. However, SAMe-TT2R2 overall score was asso-
ciated with TTR and was the only predictor of poor quality 
of anticoagulation in the multivariate analysis but only when 
a score of one was used as a cut-off instead of two. Since 
SAMe-TT2R2 score was proposed and validated by Aposto-
lakis and colleagues [30], external validation studies in pop-
ulations from various countries took place and results were 
mostly positive [35–40]. Additionally, the score was tested 
in deep venous thrombosis as opposed to non-valvular atrial 
fibrillation patients and it was also shown to have a modest 
predictive ability for the quality of INR control [41, 42]. To 
the best of our knowledge, there were no previous studies 
looking at the validity of SAMe-TT2R2 score in Arabs. Our 
study which was performed on a cohort of Qatari patients 
taking warfarin for various indications is in line with the 
results from previous studies demonstrating the predictive 
ability of the SAMe-TT2R2 score and its promising clinical 
usefulness. While we were unable to demonstrate the asso-
ciation between the individual factors of the SAMe-TT2R2 
score (apart from gender) and poor quality anticoagulation, 
the whole model still performed well when TTR of < 65% 
or < 70% were used as threshold for poor anticoagulation. 
We believe that this limitation is due primarily to the small 
sample size of the cohort used. Since one of the main objec-
tives of this study was to determine the impact of genetic 
variants in CYP2C9, VKORC1, and CYP2F4 on the level of 
INR control and the ability of these factors to improve the 
predictive ability of the SAMe-TT2R2 score, we restricted 
the inclusion in the study to Qatari patients with available 
genetic data.
Several limitations of the present study must be noted. 
The study had a small sample size. However, due to the 
limited number of Qatari patients on warfarin (about 1000 
patients) [43], and the necessity to have genetic data for the 
included subjects, a larger sample was difficult to attain. As 
a retrospective study, control for bias and other potential 
confounding variables cannot be entirely eliminated. Lastly, 
we were unable to test the effect of SAMe-TT2R2 score on 
predicting efficacy and safety outcomes as this data was not 
reported consistently and was lacking accuracy.
In conclusion, SAMe-TT2R2 score was predictive for the 
poor quality of anticoagulation in a retrospective cohort of 
Qatari patients using warfarin. However, genetic factors 
were not associated with the quality of anticoagulation and 
did not add to the predictive ability of SAMe-TT2R2 score.
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